The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion

Background In spite of potent first-line therapies for chronic lymphocytic leukemia, treatment remains palliative and all patients frequently relapse. Treatment options for these patients are more limited. BL22 is a recombinant protein composed of the variable region of a monoclonal antibody that bi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Viola Biberacher, Thomas Decker, Madlen Oelsner, Michaela Wagner, Christian Bogner, Burkhard Schmidt, Robert J. Kreitman, Christian Peschel, Ira Pastan, Christian Meyer zum Büschenfelde, Ingo Ringshausen
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2012-05-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/6305
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!